Novartis participated in the series A round for Intellia, which was co-launched by biotechnology developer Caribou.

Surgical glue developer LifeBond has raised half of the $25m it has targeted for its series D round, with series C investor Johnson & Johnson returning.

Immunotherapy firm Juno Therapeutics looks to add $150m to its $310m with initial public offering.

The pharmaceutical firm will fund startups and entrepreneurs across India with a fund that could be as large as $16m.

The corporates are sponsoring the Germany-based accelerator, which will invest $25,000 in startups developing eye treatments.

The bioopharmaceutical company raised $145.8m in its initial public offering, while AstraZeneca invested $20m in a concurrent private placement.

Two Auckland spin-outs and Fraunhofer Institute collaborate to bring an exoskeleton arm brace to market within three years.

Washington spin-out Vicis secures funding for development of American football helmet aimed at reducing concussions.

Healthcare company Spirometrix has raised $8.6m in a series B round that included $5m from manufacturing partner NGK Spark Plug as an strategic investment.